Fort Washington Investment Advisors Inc. OH Has $22.68 Million Holdings in Encompass Health Corporation $EHC

Fort Washington Investment Advisors Inc. OH lowered its position in Encompass Health Corporation (NYSE:EHC) by 12.4% during the first quarter, according to its most recent filing with the SEC. The firm owned 234,425 shares of the company’s stock after selling 33,233 shares during the period. Fort Washington Investment Advisors Inc. OH’s holdings in Encompass Health were worth $22,676,000 as of its most recent filing with the SEC.

Several other large investors also recently modified their holdings of the company. EP Wealth Advisors LLC raised its stake in Encompass Health by 2.4% during the second quarter. EP Wealth Advisors LLC now owns 3,694 shares of the company’s stock worth $453,000 after buying an additional 88 shares during the last quarter. Allworth Financial LP boosted its position in Encompass Health by 14.7% during the third quarter. Allworth Financial LP now owns 701 shares of the company’s stock valued at $89,000 after acquiring an additional 90 shares during the last quarter. Gibson Capital LLC grew its holdings in Encompass Health by 4.3% during the 1st quarter. Gibson Capital LLC now owns 2,431 shares of the company’s stock worth $235,000 after acquiring an additional 101 shares during the period. Leuthold Group LLC grew its holdings in Encompass Health by 0.3% during the 4th quarter. Leuthold Group LLC now owns 31,168 shares of the company’s stock worth $3,308,000 after acquiring an additional 104 shares during the period. Finally, Covestor Ltd raised its position in shares of Encompass Health by 24.4% in the 4th quarter. Covestor Ltd now owns 540 shares of the company’s stock worth $57,000 after acquiring an additional 106 shares in the last quarter. 97.25% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

EHC has been the topic of several research analyst reports. Wall Street Zen upgraded Encompass Health from a “hold” rating to a “buy” rating in a research report on Saturday, May 2nd. Leerink Partners set a $152.00 price target on Encompass Health in a research note on Friday, May 22nd. Weiss Ratings cut Encompass Health from a “buy (b-)” rating to a “hold (c+)” rating in a report on Friday. Barclays reduced their price objective on shares of Encompass Health from $153.00 to $140.00 and set an “overweight” rating for the company in a research report on Tuesday, May 5th. Finally, TD Cowen began coverage on shares of Encompass Health in a research note on Thursday, May 28th. They issued a “buy” rating and a $125.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, Encompass Health currently has an average rating of “Moderate Buy” and an average target price of $143.86.

Insider Transactions at Encompass Health

In related news, EVP Patrick William Tuer sold 682 shares of Encompass Health stock in a transaction on Monday, May 11th. The shares were sold at an average price of $104.56, for a total value of $71,309.92. Following the completion of the sale, the executive vice president owned 24,755 shares of the company’s stock, valued at approximately $2,588,382.80. This trade represents a 2.68% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 1.80% of the company’s stock.

Encompass Health Stock Performance

Shares of Encompass Health stock opened at $101.33 on Monday. Encompass Health Corporation has a one year low of $92.77 and a one year high of $127.99. The firm has a market capitalization of $10.05 billion, a price-to-earnings ratio of 16.92, a PEG ratio of 2.21 and a beta of 0.72. The business has a 50-day simple moving average of $103.25 and a 200 day simple moving average of $103.54. The company has a debt-to-equity ratio of 0.76, a current ratio of 1.17 and a quick ratio of 1.17.

Encompass Health (NYSE:EHC) last announced its quarterly earnings results on Thursday, April 30th. The company reported $1.60 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.51 by $0.09. Encompass Health had a return on equity of 18.28% and a net margin of 10.04%.The business had revenue of $1.59 billion for the quarter, compared to analyst estimates of $1.57 billion. During the same quarter in the prior year, the company earned $1.37 earnings per share. The company’s quarterly revenue was up 9.0% on a year-over-year basis. Encompass Health has set its FY 2026 guidance at 5.890-6.110 EPS. On average, research analysts anticipate that Encompass Health Corporation will post 5.97 earnings per share for the current fiscal year.

Encompass Health Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, July 15th. Investors of record on Wednesday, July 1st will be issued a $0.19 dividend. This represents a $0.76 dividend on an annualized basis and a dividend yield of 0.8%. The ex-dividend date is Wednesday, July 1st. Encompass Health’s dividend payout ratio (DPR) is currently 12.69%.

Encompass Health Profile

Encompass Health Corporation is a leading provider of post‐acute healthcare services in the United States, operating a comprehensive network of inpatient rehabilitation hospitals and home health and hospice agencies. Its inpatient rehabilitation hospitals offer intensive therapy programs for patients recovering from conditions such as stroke, brain injury, spinal cord injury, cardiac and pulmonary disorders, and orthopedic procedures. Through its home health segment, Encompass Health delivers skilled nursing, physical therapy, occupational therapy and speech therapy to patients in the comfort of their homes, while its hospice services provide end‐of‐life care focused on symptom management and emotional support for patients and families.

Founded in 1984 as HealthSouth Corporation and rebranded as Encompass Health in 2018, the company has grown organically and through acquisitions to serve patients across more than 30 states.